The complex genetic landscape of Acute Myeloid Leukemia (AML), marked by chromosomal alterations and gene mutations, necessitates innovative approaches.

The Need

AML poses a significant challenge in the realm of hematologic malignancies, demanding both prognostic markers and novel treatments. Current gaps in understanding the complex genetic landscape, in particular the functional implications of the Epithelial Growth Factor-Like 7 (EGFL7) gene in AML, coupled with the need for prognostic markers, call for transformative solutions to enhance therapeutic outcomes.

The Technology

Researchers at The Ohio State University have developed a groundbreaking technology focusing on the pivotal role of EGFL7 in hematologic malignancies, marking a paradigm shift in AML treatment. Specifically, anti-EGFL7 antibodies emerge as a promising tool for preventing or treating hematologic malignancies. Additionally, EGFL7 expression levels serve as a prognostic marker, predicting a subject’s responsiveness to therapeutic agents, Leveraging EGFL7’s significance in hematopoiesis, recombinant EGFL7 presents a novel approach for expanding hematopoietic stem and progenitor cells (HSPCs).

Commercial Applications

• Treatment of AML

• Prognostic Marker

• Hematopoietic Stem Cell Expansion

• Diagnostic Tools

• Therapeutic Response Prediction: Method for predicting responsiveness enhances treatment planning

Benefits/Advantages

• Targeted Treatment: Anti-EGFL7 antibodies offer a precise and effective therapeutic approach.

• Personalized Medicine: EGFL7 expression levels enable tailored treatment strategies.

• Hematopoietic Support: Recombinant EGFL7 facilitates the expansion of vital HSPCs.

• Diagnostic Precision: EGFL7 serves as a reliable marker for hematologic malignancies.

• Therapeutic Guidance: Method for predicting responsiveness enhances treatment planning.

Issued US Patent